Tricyclic heteraryl compounds as sting activators
US-2020040009-A1 · Feb 6, 2020 · US
Modulators of STING (stimulator of interferon genes)
US11964978B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11964978-B2 |
| Application number | US-202217693197-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2022 |
| Priority date | Mar 18, 2021 |
| Publication date | Apr 23, 2024 |
| Grant date | Apr 23, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds of the general formula (I):and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
First claim
Opening claim text (preview).
We claim: 1. A compound having the structure: 2. A compound having the structure: or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- C07D487/04Primary
Ortho-condensed systems · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
Antineoplastic agents · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11964978B2 cover?
- Provided herein are compounds of the general formula (I):and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).